← 返回

T 细胞微环境影响与治疗机会:应用于人睾丸生殖细胞肿瘤

英文原题:T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors.

查看英文原题

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors.

PubMed 2026/03/03(内容时间) Andrology Q1 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

睾丸生殖细胞肿瘤(TGCT)是青少年和年轻成年男性中最常见的恶性肿瘤,然而对其肿瘤微环境(TME)的免疫和细胞机制仍知之甚少。

在此,我们对TGCT的病理生物学进行了全面综述,重点关注免疫景观,特别是肿瘤浸润性T淋巴细胞的作用。哺乳动物睾丸是一个免疫豁免器官,由体细胞(Sertoli细胞和Leydig细胞)与常驻免疫细胞群的协同作用维持,共同促进免疫耐受并抑制有害的炎症反应。TGCT中免疫豁免被破坏,导致免疫细胞亚群(如巨噬细胞、肥大细胞、树突状细胞,尤其是T细胞)的组成和功能发生显著改变。CD4+ T细胞亚群(Th1、Th2、Th9、Th17、Th22、Treg和Tfh)以及CD8+ T细胞亚群(Tc1、Tc2、Tc9、Tc17和Tc22)的表型多样性和功能适应性,就其抗肿瘤免疫应答、调节免疫调控以及促进TGCT TME中肿瘤免疫逃逸的作用进行了批判性评估。尽管靶向PD-1/PD-L1和CTLA4的免疫检查点抑制剂等免疫疗法以及其他恶性肿瘤中新兴的CAR-T 细胞策略取得了成功,但由于睾丸独特的免疫环境和对TME中T细胞动态的有限了解,它们在TGCT中的疗效有限。单细胞转录组学和临床研究的最新进展凸显了对TGCT TME中T细胞亚群及其细胞间相互作用进行高分辨率表征的必要性。阐明这些机制对于合理开发新型免疫治疗策略至关重要,这些策略旨在克服耐药性、减少长期治疗相关后遗症,并改善TGCT患者的临床结局。

展开英文摘要原文

Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood.

Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor-infiltrating T lymphocytes. The mammalian testis represents an immune-privileged organ maintained by the coordinated actions of somatic cells (Sertoli and Leydig cells) and resident immune populations that collectively foster immune tolerance and suppress deleterious inflammatory responses. Immune privilege is disrupted in TGCT, resulting in significant alterations in the composition and function of immune cell subsets such as macrophages, mast cells, dendritic cells, and especially T cells. The phenotypic diversity and functional adaptability of CD4 + T cell subsets (Th1, Th2, Th9, Th17, Th22, Treg, and Tfh) along with CD8 + T cell subsets (Tc1, Tc2, Tc9, Tc17, and Tc22) are critically evaluated in terms of their roles in anti-tumor immune responses, modulating immune regulation, and enabling tumor immune evasion within the TME of TGCT.

Despite the success of immunotherapies such as immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA4, and emerging CAR-T cell strategies in other malignancies, their efficacy in TGCT is limited due to the unique testicular immune milieu and limited understanding of T cell dynamics in TME.

Recent advances in single-cell transcriptomics and clinical studies highlight the necessity for high-resolution characterization of T cell subpopulations and their intercellular interactions within the TGCT TME. Elucidating these mechanisms is critical for the rational development of novel immunotherapeutic strategies aimed at overcoming resistance, minimizing long-term treatment-related sequelae, and enhancing clinical outcomes for TGCT patients.

论文信息

作者
Islam R、Figura M、Heyer J、Lieber S、Huber M、Loveland KL、Schuppe HC、Fietz D
单位
Institute For Veterinary Anatomy, Histology and Embryology, Justus Liebig University Giessen, Giessen, Germany.Germany
文献类型
综述
期刊
Andrology2026 Mar 3
原文标识
PubMed 41773555 · DOI 10.1111/andr.70200